Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Subcutaneous ALXN1830 in Healthy Participants
NCT04730804Phase 1Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orilanolimab in generalized myasthenia gravis (gMG) and warm autoimmune hemolytic anemia (wAIHA) (6 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Mar 2021; status: terminated.
02
Drugs
orilanolimab
03
Conditions
generalized myasthenia gravis (gMG)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT04730804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730804.